Jeffrey M Bernitz
Overview
Explore the profile of Jeffrey M Bernitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bernitz J, Rapp K, Daniel M, Shcherbinin D, Yuan Y, Gomes A, et al.
Stem Cell Reports
. 2020 Apr;
14(4):561-574.
PMID: 32243840
Hematopoietic stem cells (HSCs) exist in a dormant state and progressively lose regenerative potency as they undergo successive divisions. Why this functional decline occurs and how this information is encoded...
2.
Liang R, Arif T, Kalmykova S, Kasianov A, Lin M, Menon V, et al.
Cell Stem Cell
. 2020 Feb;
26(3):359-376.e7.
PMID: 32109377
Quiescence is a fundamental property that maintains hematopoietic stem cell (HSC) potency throughout life. Quiescent HSCs are thought to rely on glycolysis for their energy, but the overall metabolic properties...
3.
Daniel M, Sachs D, Bernitz J, Fstkchyan Y, Rapp K, Satija N, et al.
FEBS Lett
. 2019 Sep;
593(23):3266-3287.
PMID: 31557312
Transcription factor (TF)-based reprogramming of somatic tissues holds great promise for regenerative medicine. Previously, we demonstrated that the TFs GATA2, GFI1B, and FOS convert mouse and human fibroblasts to hemogenic...
4.
Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism
Kim H, Yoo S, Zhou R, Xu A, Bernitz J, Yuan Y, et al.
Proc Natl Acad Sci U S A
. 2018 Nov;
115(47):E11128-E11137.
PMID: 30385632
Osteosarcoma (OS), the most common primary bone tumor, is highly metastatic with high chemotherapeutic resistance and poor survival rates. Using induced pluripotent stem cells (iPSCs) generated from Li-Fraumeni syndrome (LFS)...
5.
Bernitz J, Daniel M, Fstkchyan Y, Moore K
Blood
. 2017 Feb;
129(14):1901-1912.
PMID: 28179275
Granulocyte colony-stimulating factor (G-CSF) is used clinically to treat leukopenia and to enforce hematopoietic stem cell (HSC) mobilization to the peripheral blood (PB). However, G-CSF is also produced in response...
6.
Daniel M, Pereira C, Bernitz J, Lemischka I, Moore K
J Vis Exp
. 2017 Jan;
(118).
PMID: 28060340
This protocol details the induction of a hemogenic program in mouse embryonic fibroblasts (MEFs) via overexpression of transcription factors (TFs). We first designed a reporter screen using MEFs from human...
7.
Bernitz J, Kim H, MacArthur B, Sieburg H, Moore K
Cell
. 2016 Nov;
167(5):1296-1309.e10.
PMID: 27839867
The ability of cells to count and remember their divisions could underlie many alterations that occur during development, aging, and disease. We tracked the cumulative divisional history of slow-cycling hematopoietic...
8.
Kim H, Bernitz J, Lee D, Lemischka I
Stem Cells Dev
. 2014 Jul;
23(22):2673-86.
PMID: 25075441
Patient-specific induced pluripotent stem cells (iPSCs) are considered a versatile resource in the field of biomedicine. As iPSCs are generated on an individual basis, iPSCs may be the optimal cellular...